Novo Nordisk A/S (NVO)
| Market Cap | 266.18B |
| Revenue (ttm) | 40.31B |
| Net Income (ttm) | 14.02B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.14 |
| PE Ratio | 19.07 |
| Forward PE | 14.27 |
| Dividend | $1.61 (2.69%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 11,681,229 |
| Open | 58.92 |
| Previous Close | 58.33 |
| Day's Range | 58.92 - 60.18 |
| 52-Week Range | 57.00 - 148.15 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 128.00 (+113.65%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $128.0, which is an increase of 113.65% from the latest price.
News
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk is a high-quality biopharma company with a strong diabetes franchise and a booming obesity drug segment, making it an attractive growth play. Following a 50% drop from recent highs, NVO t...
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly'...
5 European stocks to watch this earnings season as Trump's tariffs hit
The scale of President Donald Trump's tariffs, along with the volatility injected by subsequent updates and reversals in policy, have so far exceeded even the most bearish forecasts. Danish shipping g...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Selling America, Buying Europe - My Picks
After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAP...
Novo Nordisk: A Price Too Low To Ignore
Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappoint...
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
BMO Capital Markets analyst Evan David Seigerman downgraded Novo Nordisk NVO from Outperform to Market Perform, lowering the price forecast from $105 to $64.
Rebecca Walser: Hold NVDA, Buy NVO & LRCX, Caution MCD
Rebecca Walser (@walserwealth) joins Diane King Hall at the NYSE site with several specific stocks to highlight. On her current list of names she likes: Novo Nordisk (NVO) and Lam Research (LRCX).
Trump signs healthcare executive order that includes a win for pharma companies
U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows Medicare to negotiate prescription drug prices, seeking to introduce a change...
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields appro...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Novo Nordisk warns consumers about counterfeit versions of Ozempic in US
Novo Nordisk said on Monday it has become aware of several hundred units of counterfeit versions of its diabetes drug Ozempic being distributed outside its authorized supply chain in the United States...
Wegovy, Zepbound makers' stocks rally as a weight-loss-drug competitor drops out
Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift in early Monday trading, after a potential competitor decided to cancel development of its GLP-1 drug.
We see about 50% upside on Novo Nordisk, but there are risks, says strategist
Michael Field, chief EMEA equity strategist at Morningstar, discusses European stocks amid tariff uncertainty.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted Spencer Perlman, director of Healthcare Research at Veda Partners, an investment advisory and consulting firm with extensive expertise in government policy analysis. During the conversa...